{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:54:05Z","timestamp":1791323645379,"version":"4.3.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jceh.2026.103593","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:26:26Z","timestamp":1781763986000},"page":"103593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking Barriers in Hepatocellular Carcinoma: Synergistic Potential of Stereotactic Body Radiotherapy Combined With Immunotherapy"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-3384","authenticated-orcid":false,"given":"Deepti","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7019-1020","authenticated-orcid":false,"given":"Babu Lal","family":"Meena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2026.103593_bib1","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jceh.2026.103593_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jceh.2026.103593_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/hepr.13612","article-title":"Report of the 21st follow-up survey of primary liver cancer in Japan (2010\u20132011)","volume":"51","author":"Kudo","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jceh.2026.103593_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"L Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib6","article-title":"Predictive factors and nomogram (MAP-BNP) for post stereotactic body radiotherapy survival in advanced hepatocellular carcinoma patients","volume":"15","author":"Sharma","year":"2025","journal-title":"J Clin Exp Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2026.103593_bib7","first-page":"86","article-title":"Liver cancer immunity","volume":"73","author":"Rizvi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103593_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00270-021-03031-9","article-title":"Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment","volume":"45","author":"Llovet","year":"2022","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.jceh.2026.103593_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri3169","article-title":"Living in the liver: hepatic infections","volume":"12","author":"Protzer","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib11","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumour-associated antigen-specific CD8(+) T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatol (Baltimore Md.)"},{"key":"10.1016\/j.jceh.2026.103593_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","article-title":"HCC and angiogenesis: possible targets and future directions","volume":"8","author":"Zhu","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.95009","article-title":"Exploring the role of the immune microenvironment in hepatocellular carcinoma: implications for immunotherapy and drug resistance","volume":"13","author":"Fu","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.jceh.2026.103593_bib14","article-title":"Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-2478(02)00176-1","article-title":"Expression of interleukin-18, interferon-gamma and interleukin-10 in hepatocellular carcinoma","volume":"84","author":"Chia","year":"2022","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jceh.2026.103593_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib17","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2026.103593_bib18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103593_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102444","article-title":"Prognostic role of serum vascular endothelial growth factor and hepatocyte growth factor post stereotactic body radiation in advanced hepatocellular carcinoma","volume":"15","author":"Pahwa","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20091918","article-title":"Tumour-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","volume":"207","author":"Quezada","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jceh.2026.103593_bib21","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.4049\/jimmunol.1101812","article-title":"Th-1 lymphocytes induce dendritic cell tumour killing activity by an IFN-gamma-dependent mechanism","volume":"187","author":"LaCasse","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib22","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41598-019-40078-8","article-title":"Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2026.103593_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/ph14010003","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: an overview","volume":"14","author":"Van Doorn","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jceh.2026.103593_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1379622","article-title":"Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma","volume":"15","author":"Akbulut","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib25","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.7150\/ijbs.70691","article-title":"New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials","volume":"18","author":"Jin","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jceh.2026.103593_bib26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00432-023-05539-8","article-title":"Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review","volume":"150","author":"Zhang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","article-title":"Combination locoregional and systemic therapies in hepatocellular carcinoma","volume":"10","author":"Zhong","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib34","article-title":"Exploring the evolving landscape of stereotactic body radiation therapy in hepatocellular carcinoma","volume":"15","author":"Sharma","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000530134","article-title":"Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases","volume":"12","author":"De","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jceh.2026.103593_bib36","article-title":"Stereotactic body radiation therapy in advanced intrahepatic cholangiocarcinoma: real-world outcomes from an Indian cohort","volume":"15","author":"Sharma","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib37","doi-asserted-by":"crossref","DOI":"10.4292\/wjgpt.v16.i4.109304","article-title":"Evolving role of radiation therapy in advanced\/metastatic intrahepatic cholangiocarcinoma","volume":"16","author":"Sharma","year":"2025","journal-title":"World J Gastrointest Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2026.103593_bib38","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update","volume":"27","author":"Reig","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib39","article-title":"2023 update of Indian national association for study of the liver consensus on management of intermediate and advanced hepatocellular carcinoma: the puri III recommendations","volume":"14","author":"Kumar","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib40","article-title":"Radiation therapy in the era of immune treatment for hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib41","article-title":"The use of artificial intelligence in stereotactic ablative body radiotherapy for hepatocellular carcinoma","volume":"12","author":"Katano","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jceh.2026.103593_bib42","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/curroncol30020190","article-title":"Stereotactic body radiotherapy for hepatocellular carcinoma: a brief overview","volume":"30","author":"Matsuo","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib43","article-title":"Outcomes after stereotactic body radiation for hepatocellular carcinoma in patients with child-pugh A versus child-pugh B\/C cirrhosis","volume":"9","author":"Diamond","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib44","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1186\/s12885-025-15061-4","article-title":"Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"25","author":"Hou","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jceh.2026.103593_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/lci2.70005","article-title":"Stereotactic body radiation therapy combined with immunotherapy for patients with hepatocellular carcinoma-a review","volume":"5","author":"Patel","year":"2024","journal-title":"Liver Int Commun"},{"key":"10.1016\/j.jceh.2026.103593_bib46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00066-023-02065-x","article-title":"Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients","volume":"199","author":"Sharma","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.jceh.2026.103593_bib47","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2022.40.16_suppl.4091","article-title":"Sequential trans-arterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy (START-FIT) for locally advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"40","author":"Chiang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.17998\/jlc.2024.02.26","article-title":"Current perspectives on radiotherapy in hepatocellular carcinoma management: a comprehensive review","volume":"24","author":"Kim","year":"2024","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.jceh.2026.103593_bib49","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232408","article-title":"CT\/MRI LI-RADS 2024 update: treatment response assessment","volume":"313","author":"Aslam","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.jceh.2026.103593_bib50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumour radiobiology of SRS and SBRT: are more than the 5 Rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1667\/RR2773.1","article-title":"Radiation-induced vascular damage in tumours: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)","volume":"177","author":"Park","year":"2012","journal-title":"Radiat Res"},{"key":"10.1016\/j.jceh.2026.103593_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568759","article-title":"Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond","volume":"11","author":"Lee","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumour immunity in immunogenic tumours","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jceh.2026.103593_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1084\/jem.191.3.423","article-title":"Consequences of cell death: exposure to necrotic tumour cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells","volume":"191","author":"Sauter","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jceh.2026.103593_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/1179064418761639","article-title":"The impact of radiation on the tumour microenvironment: effect of dose and fractionation schedules","volume":"11","author":"Arnold","year":"2018","journal-title":"Cancer Growth Metastasis"},{"key":"10.1016\/j.jceh.2026.103593_bib56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fonc.2012.00089","article-title":"Irradiation promotes an m2 macrophage phenotype in tumour hypoxia","volume":"2","author":"Chiang","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib57","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib58","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.jceh.2026.103593_bib59","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jceh.2026.103593_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3350\/cmh.2020.0095","article-title":"Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: a murine model study","volume":"27","author":"Yoo","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2026.103593_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.medj.2023.02.003","article-title":"The abscopal effect in patients with cancer receiving immunotherapy","volume":"4","author":"Nelson","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.jceh.2026.103593_bib62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3350\/cmh.2020.0297","article-title":"Exploring the mythical abscopal effect: radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Mol Hepatology"},{"key":"10.1016\/j.jceh.2026.103593_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104191","article-title":"Combination treatment of HCC with SBRT and immune checkpoint inhibition","volume":"192","author":"Podesta","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jceh.2026.103593_bib64","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12967-023-04386-y","article-title":"Advances in radiotherapy and immunity in hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jceh.2026.103593_bib65","first-page":"50","article-title":"Stereotactic body radiation therapy (SBRT) plus immune checkpoint inhibitors (ICI) in hepatocellular carcinoma and cholangiocarcinoma","volume":"15","author":"Iang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jceh.2026.103593_bib66","doi-asserted-by":"crossref","first-page":"10427","DOI":"10.1007\/s13277-016-4916-2","article-title":"The clinical and prognostic significance of CD14+HLA-DR-\/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy","volume":"37","author":"Wang","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jceh.2026.103593_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fonc.2020.00004","article-title":"Hypofractionated irradiation suppressed the off-target mouse Hepatocarcinoma growth by inhibiting myeloid-derived suppressor cell-mediated immune suppression","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib68","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1158\/1078-0432.CCR-05-2721","article-title":"Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma","volume":"12","author":"Chung","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jceh.2026.103593_bib69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2012.10.024","article-title":"Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo","volume":"329","author":"Yu","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jceh.2026.103593_bib71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12032-021-01503-z","article-title":"The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors","volume":"38","author":"Une","year":"2021","journal-title":"Med Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jceh.2026.103593_bib73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2019.02.046","article-title":"Immunomodulatory effects of stereotactic body radiation therapy: preclinical insights and clinical opportunities","volume":"110","author":"Marciscano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib76","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trecan.2019.07.006","article-title":"Tissue site and the cancer immunity cycle","volume":"5","author":"Horton","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jceh.2026.103593_bib75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib77","first-page":"1058","article-title":"Exploring the concept of radiation \"booster shot\" in combination with an Anti-PD-L1 mAb to enhance anti-tumor immune effects in mouse pancreas tumors","volume":"5","author":"Chuong","year":"2017","journal-title":"J Clin Oncol Res"},{"key":"10.1016\/j.jceh.2026.103593_bib78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.canlet.2015.03.024","article-title":"Awakening the immune system with radiation: optimal dose and fractionation","volume":"368","author":"Gandhi","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jceh.2026.103593_bib79","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib80","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib81","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.21037\/jgo-2024-1011","article-title":"Efficacy of stereotactic body radiotherapy in hepatocellular carcinoma with adrenal metastases: a retrospective analysis","volume":"16","author":"Cheng","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000773","article-title":"Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma","volume":"8","author":"Curti","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jceh.2026.103593_bib83","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.ijrobp.2018.04.038","article-title":"Stereotactic ablative radiation therapy induces systemic differences in peripheral blood immunophenotype dependent on irradiated site","volume":"101","author":"McGee","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jceh.2026.103593_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100812","article-title":"Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumour model","volume":"31","author":"Telarovic","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.jceh.2026.103593_bib86","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib87","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib88","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jceh.2026.103593_bib89","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy","volume":"101","author":"Lan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib90","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1182\/bloodadvances.2018023119","article-title":"Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions","volume":"2","author":"Dutt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jceh.2026.103593_bib91","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jceh.2026.103593_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jceh.2026.103593_bib93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1667\/RR3819.1","article-title":"In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation","volume":"182","author":"Kanagavelu","year":"2014","journal-title":"Radiat Res"},{"key":"10.1016\/j.jceh.2026.103593_bib94","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijrobp.2018.10.009","article-title":"An antitumor immune response is evoked by partial-volume single-dose radiation in 2 murine models","volume":"103","author":"Markovsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2009.06.022","article-title":"Don't squeeze hypofractionated schedules into too-short overall times","volume":"75","author":"Fowler","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib96","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103593_bib97","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1593\/tlo.12280","article-title":"A systemic complete response of metastatic melanoma to local radiation and immunotherapy","volume":"5","author":"Hiniker","year":"2012","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67528-4","article-title":"Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial","author":"Tang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jceh.2026.103593_bib99","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.4049\/jimmunol.1202612","article-title":"Radiation-induced equilibrium is a balance between tumour cell proliferation and T cell-mediated killing","volume":"190","author":"Liang","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","article-title":"Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jceh.2026.103593_bib101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2326-6066.CIR-13-0031-T","article-title":"Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumour immunity","volume":"2","author":"Redmond","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jceh.2026.103593_bib102","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/PPO.0000000000000668","article-title":"Is apparent diffusion coefficient established as an imaging biomarker for stereotactic body radiation therapy assessment in hepatocellular carcinoma?","volume":"29","author":"Cao","year":"2023","journal-title":"Cancer J"},{"key":"10.1016\/j.jceh.2026.103593_bib103","doi-asserted-by":"crossref","DOI":"10.1177\/15593258221097589","article-title":"Screening of prognostic biomarkers for stereotactic body radiation therapy in primary liver cancer","volume":"20","author":"Liang","year":"2022","journal-title":"Dose Response"},{"key":"10.1016\/j.jceh.2026.103593_bib104","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity","volume":"4","author":"Lewis","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2026.103593_bib105","doi-asserted-by":"crossref","unstructured":"O'Kane G, Mesci A, Jang R, Barry A, Bocaya C, Boukhaled G, et al. Pembrolizumab and Stereotactic Body Radiotherapy Combined in Advanced Hepatocellular Carcinoma Post sorafenib\u2013 A Phase II Trial (PEMRAD), JHEP Reports. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101658.","DOI":"10.1016\/j.jhepr.2025.101658"},{"key":"10.1016\/j.jceh.2026.103593_bib106","article-title":"Concurrent radiation and immunotherapy for unresectable hepatocellular carcinoma with extensive portal vein tumor thrombus","volume":"10","author":"Krishnamurthy","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib107","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1002\/cam4.2570","article-title":"Clinical significance of radiotherapy before and\/or during nivolumab treatment in hepatocellular carcinoma","volume":"8","author":"Yu","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jceh.2026.103593_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.798832","article-title":"Combined stereotactic body radiotherapy and immunotherapy versus transarterial chemoembolization in locally advanced hepatocellular carcinoma: a propensity score matching analysis","volume":"11","author":"Chiang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib109","article-title":"Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: a phase II study","volume":"6","author":"Kim","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2026.103593_bib110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib111","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae209","article-title":"Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumour thrombosis","volume":"30","author":"Ma","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.jceh.2026.103593_bib112","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ijrobp.2024.03.035","article-title":"Stereotactic body radiotherapy combined with lenvatinib with or without PD-1 inhibitors as initial treatment for unresectable hepatocellular carcinoma","volume":"120","author":"Wang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jceh.2026.103593_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972503","article-title":"PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: a propensity score matching study","volume":"13","author":"Su","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103593_bib114","article-title":"Toripalimab in combination with anlotinib for unresectable hepatocellular carcinoma after SBRT: a prospective, single-arm, single-center clinical study","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.686621","article-title":"Safety of PD-1\/PD-L1 inhibitors combined with palliative radiotherapy and anti-angiogenic therapy in advanced hepatocellular carcinoma","volume":"11","author":"Zhong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jceh.2026.103593_bib116","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41467-024-47420-3","article-title":"Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the notable-HCC phase 1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jceh.2026.103593_bib117","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2026.103593_bib118","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:45:18Z","timestamp":1791323118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688326001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0973688326001258"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103593","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking Barriers in Hepatocellular Carcinoma: Synergistic Potential of Stereotactic Body Radiotherapy Combined With Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103593"}}